Collegium Pharmaceutical, Inc. (COLL)
23.84
-0.46
(-1.89%)
USD |
NASDAQ |
Sep 03, 13:39
Collegium Pharmaceutical Cash from Investing (Quarterly) : -502.59M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -502.59M |
| March 31, 2026 | 1.627M |
| December 31, 2025 | -20.07M |
| September 30, 2025 | -30.87M |
| June 30, 2025 | -2.915M |
| March 31, 2025 | -9.68M |
| December 31, 2024 | -11.76M |
| September 30, 2024 | -248.96M |
| June 30, 2024 | -8.906M |
| March 31, 2024 | -18.13M |
| December 31, 2023 | -25.10M |
| September 30, 2023 | -3.822M |
| June 30, 2023 | -41.72M |
| March 31, 2023 | -0.176M |
| December 31, 2022 | -0.94M |
| September 30, 2022 | -0.113M |
| June 30, 2022 | -0.461M |
| March 31, 2022 | -572.18M |
| December 31, 2021 | -0.515M |
| September 30, 2021 | -0.276M |
| June 30, 2021 | -0.725M |
| March 31, 2021 | -0.428M |
| December 31, 2020 | -1.481M |
| Date | Value |
|---|---|
| September 30, 2020 | -2.403M |
| June 30, 2020 | -2.241M |
| March 31, 2020 | -367.65M |
| December 31, 2019 | -0.889M |
| September 30, 2019 | -1.351M |
| June 30, 2019 | -0.875M |
| March 31, 2019 | -3.323M |
| December 31, 2018 | -1.773M |
| September 30, 2018 | -2.717M |
| June 30, 2018 | -0.747M |
| March 31, 2018 | -19.12M |
| December 31, 2017 | -0.172M |
| September 30, 2017 | -0.34M |
| June 30, 2017 | -0.449M |
| March 31, 2017 | -0.029M |
| December 31, 2016 | -0.341M |
| September 30, 2016 | -0.111M |
| June 30, 2016 | -2.525M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | -0.187M |
| September 30, 2015 | -0.152M |
| June 30, 2015 | -0.023M |
| March 31, 2015 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Innoviva, Inc. | -55.26M |
| Zevra Therapeutics, Inc. | 31.45M |
| Supernus Pharmaceuticals, Inc. | 7.094M |
| Indivior Pharmaceuticals, Inc. | -7.942M |
| Crinetics Pharmaceuticals, Inc. | 26.29M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 71.32M |
| Cash from Financing (Quarterly) | 292.09M |
| Free Cash Flow | 328.28M |
| Free Cash Flow Per Share (Quarterly) | 2.182 |
| Free Cash Flow to Equity (Quarterly) | -217.36M |
| Free Cash Flow to Firm (Quarterly) | 92.54M |
| Free Cash Flow Yield | 36.23% |